FUNDING AND RETURNS
The initial seed round raise will extend beyond release and include contingency funds to provide security for product-development efforts. Concurrent to the release of the Beta version of the application, WindowMirror will be actively seeking its Series-A raise.
In year one, WindowMirror will focus on development, growth, and impact. We will be lean, virtual, and agile, all while keeping to our vision of building the premier mobile experience for persons with dementia-spectrum needs.
Anticipating a release, iterating swiftly, and relying on solid relationships with organizations and leaders in the dementia care space, WindowMirror intends to execute a culture grab within the cognitive-impairment community. Targeting that market through grassroots engagement and expert consultation, WindowMirror will aims to achieve 100,000 paid subscribers by end of year one.
The 3-year pro forma shows how dynamic growth may look following Series-A funding. WindowMirror seeks to extend to an international brand, hitting target markets strategically. We will be focused on impact and reaching the 44 million persons living with dementia worldwide by year three, resulting in 500,000 paid subscribers.
WindowMirror's BUTTERFLY is a free download. This will give you the dementia-friendly and capable always-listening speech-to-text experience and ability to share in a micro social network with your closest loved ones, to engage in palliative story share.
Subscription as a Service (SaaS): For a small monthly fee you will be able to access and track analytics, use geo-tracking, geo-fencing, and other aspects that come with our premium services.
DATA: We will leverage palliative care and clinical data generated that will be useful to healthcare providers, insurance providers, and pharmaceutical companies. We believe our data will help improve outcomes, drive down the rate of hospital readmission, and better understand and track medication performance.
License: We will seek to license downloads of premium and all data aggregation to governments, healthcare providers, insurance providers, and pharmaceutical companies.